People with Alzheimer’s disease wanted for evaluating a new research drug that may improve their cognitive function

Tweet about this on TwitterShare on FacebookShare on Google+Share on LinkedInEmail this to someonePrint this page

The purpose of the study is to find out whether a new research drug, given in addition to the medication Donepezil, can improve the cognitive function in people with Alzheimer’s disease.

We are looking for people with mild to moderate Alzheimer’s disease (memory score of 12-24 on the Mmse assessment) who have been taking 10mg Donepezil for at least 3 months before entering the study. Caregivers can give consent on the patient’s behalf if the patient does not have capacity to consent.

This study will consist of screening, treatment and follow-up phases over about 7 months. The study will include 7 visits to the clinic and 1 additional visit after the participant has stopped taking the study medication.

At each visit the participant will be asked questions by their study doctor to assess their general state and the evolution (progress) of their illness, as well as the safety and efficacy of the study medication. These will be evaluated through several kinds of scales.

During this study the participant will be asked to undertake some memory, language, reading, orientation and figure-copying tests. They will also be asked to answer some questions about how they feel and how they are coping in daily life and if they are taking their medication regularly.

The caregiver will also be asked some questions about the participant’s condition and progress. Therefore, it is extremely important this person will be able to accompany the participant to each visit at the clinic.

Date required

Ongoing

Organisation

Oxford Health NHS Foundation Trust

Contact

Debbie Cooper
deborah.cooper@oxfordhealth.nhs.uk
01865 902124